Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus

NCT06632561 is registered in ClinicalTrials.gov with Ashraf Wasfy Beshay Aziz as lead sponsor.

NCT NCT06632561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06632561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
Lead sponsor
Ashraf Wasfy Beshay Aziz
Phase
Phase 4
Overall status
Completed
Start date
July 26, 2021
Completion date
March 14, 2022
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction